We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Zoetis (ZTS - Free Report) closed at $79.57, marking a -2.25% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.5%. Elsewhere, the Dow saw an upswing of 0.7%, while the tech-heavy Nasdaq appreciated by 0.31%.
The animal health company's shares have seen an increase of 7.84% over the last month, surpassing the Medical sector's gain of 5.49% and the S&P 500's loss of 0.23%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company is expected to report EPS of $1.85, up 5.11% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $2.49 billion, showing a 1.39% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.91 per share and a revenue of $9.75 billion, indicating changes of +7.8% and +2.96%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Zoetis. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.04% increase. Right now, Zoetis possesses a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 11.78. This denotes a discount relative to the industry average Forward P/E of 16.32.
One should further note that ZTS currently holds a PEG ratio of 1.26. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Drugs industry held an average PEG ratio of 1.55.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 41% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
In the latest trading session, Zoetis (ZTS - Free Report) closed at $79.57, marking a -2.25% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.5%. Elsewhere, the Dow saw an upswing of 0.7%, while the tech-heavy Nasdaq appreciated by 0.31%.
The animal health company's shares have seen an increase of 7.84% over the last month, surpassing the Medical sector's gain of 5.49% and the S&P 500's loss of 0.23%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company is expected to report EPS of $1.85, up 5.11% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $2.49 billion, showing a 1.39% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.91 per share and a revenue of $9.75 billion, indicating changes of +7.8% and +2.96%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Zoetis. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.04% increase. Right now, Zoetis possesses a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 11.78. This denotes a discount relative to the industry average Forward P/E of 16.32.
One should further note that ZTS currently holds a PEG ratio of 1.26. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Drugs industry held an average PEG ratio of 1.55.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 144, putting it in the bottom 41% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.